In summary, we proposed and validated the mechanistic hypothesis that circPTPN12 activated the hnRNPM-mediated IL-6/STAT3 pathway and therefore promoted the progression and sunitinib resistance of RCC. This evidence concerns the gene STAT3 and renal cell carcinoma.